6-(4-tert-butyl-3-chlorophenyl)pyrimidine-4-carboxylic acid, and 7-chloro-8-cyclopropoxy-5H-chromeno[4,3-d]pyrimidine-4-carboxylic acid.

35. A pharmaceutical composition comprising at least one chemical entity of any one of claims 1 to 34 and at least one pharmaceutically acceptable excipient.

36. ~~A method of treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment which method comprises administering to the subject~~Use of a therapeutically effective amount of at least one chemical entity of any one of claims 1 to 34 in the manufacture of a medicament for treating a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity in a subject in need of such a treatment.

37. The ~~method~~use of claim 36 wherein said condition or disorder involves a neurodegenerative pathology.

38. A packaged pharmaceutical composition comprising at least one pharmaceutical composition according claim 35 and instructions for using the composition to treat a subject suffering from a condition or disorder mediated by Kynurenine 3-mono-oxygenase activity.

39. The packaged pharmaceutical composition according to claim 38, wherein the condition or disorder is Huntington's disease.